Nutlin-3a

目录号:S8059 别名: (-)-Nutlin-3

Nutlin-3a Chemical Structure

Molecular Weight(MW): 581.49

Nutlin-3a是Nutlin-3的活性对映体,抑制p53/MDM2相互作用,无细胞试验中IC50为90 nM。

规格 价格 库存 购买数量  
RMB 1624.68 现货
RMB 5480.74 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的4个实验数据:

  • Twenty-four hours after plating 1×105 Shh-EGFP cells, media was changed to serum-free media containing vehicle, 8µM Nutlin-3a, and/or Shh (3µg/mL). Cells were also transduced with lentivirus containing pLKO.1 empty vector or LentiORF-YFP-WIP1. 48 hours later, cells were fixed in 4% paraformaldehyde, permeabilized, incubated with α-WIP1 or α-Ki-67 antibody, and mounted using media containing DAPI. Scale bar, 100µm.

    Oncogene, 2016, 35(42):5552-5564. Nutlin-3a purchased from Selleck.

    Assessment of cell viability with WST1 tetrazolium salt assays in TP53 WT and KO isogenic cell lines after exposure to Nutlin-3a.

    Br J Haematol, 2017, 177(1):80-94. Nutlin-3a purchased from Selleck.

  • Nutlin-3a preserved p53 expression without influencing high glucose (HG)-induced podocyte impairment. A-D: cultured podocytes were pre-treated by nutlin-3a for 2 hrs before subjected to HG treatment. Western blotting gel documents (A) and summarized data (B) showing the expression of p53 and MDM2 in podocytes under HG exposure for 24 hrs. n = 4. Western blotting gel documents (C) and summarized data (D) showing the expression of Desmin in podocytes under HG exposure for 24 hrs. n = 3. *P < 0.05 vs. Ctrl, #P < 0.05 vs. Vehl + HG. Ctrl: control; Vehl: vehicle; nutlin-3a: nutlin-3a treatment.

    J Cell Mol Med, 2017, 21(12):3435-3444. Nutlin-3a purchased from Selleck.

    Protein expression of TP53 and p21 of ovarian cancer cell lines after treated with Nutlin-3a for 24, 48 and 72 hours at their corresponding IC50 as indicated. C, untreated control; *, cancer cell lines carrying TP53 mutation. Het, heterozygous TP53 mutation; hom, homozygous TP53 mutation.

    PLoS One, 2015, 10(8):e0135101.. Nutlin-3a purchased from Selleck.

产品安全说明书

Mdm2抑制剂选择性比较

生物活性

产品描述 Nutlin-3a是Nutlin-3的活性对映体,抑制p53/MDM2相互作用,无细胞试验中IC50为90 nM。
特性 高度选择性的MDM2抑制剂与对MDMX低得多的效果。对含野生型p53的肿瘤最有效。
靶点
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
体外研究

Nutlin-3α从MDM2蛋白的结合口袋置换p53,由此将p53从抑制和蛋白酶体降解状态释放出来,从而导致诱导其下游靶点,细胞周期停滞和细胞凋亡。七天孵育10 μM nutlin-3a导致了NIH3T3细胞的生长抑制达90%以上。[1] Nutlin-3α稳定并激活p53基因,以剂量依赖性的方式诱导p21的表达。[1] Nutlin-3A有效地减少S期细胞至0.2-2%,并增加了G1-和G2/M期细胞。[1] 在40小时后,Nutlin-3a诱导约60% SJSA-1和MHM细胞的凋亡,而到60小时后,凋亡细胞分别达到85%和65%。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NVrnTWluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTlOIFKSzVyPUCuOlEzOzdizszN MXXTRW5ITVJ?
H4 MknXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL2SHZKSzVyPUCuOlYzQCEQvF2= Mk\mV2FPT0WU
PA-1 M3Tkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PJSGlEPTB;MD64O|A6PiEQvF2= NGG5RpRUSU6JRWK=
NKM-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLGTWM2OD1zLkC0PVMyKM7:TR?= M36wdXNCVkeHUh?=
NEC8 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHm5O3hKSzVyPUGuNlE2PzJizszN NVv6SpA4W0GQR1XS
EoL-1-cell MnnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnubW9KSzVyPUGuNlY4ODFizszN M4C2S3NCVkeHUh?=
K5 NF[5cJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTFwNEKwO|Ih|ryP MV\TRW5ITVJ?
QIMR-WIL NUXUV|BzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTUTWM2OD1zLk[wPFU1KM7:TR?= NYLZU25qW0GQR1XS
MOLT-16 MmKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTqTWM2OD1zLke4OlA1KM7:TR?= M2mwdHNCVkeHUh?=
CHP-212 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPpTWM2OD1zLkixN|Y6KM7:TR?= M1znRXNCVkeHUh?=
CTB-1 NVT1O5c4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTJwMEKyOFYh|ryP MWPTRW5ITVJ?
MOLT-4 NVKwU5d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJwM{K4OVMh|ryP NGTMNJJUSU6JRWK=
A101D NHfNe4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPZTWM2OD1{LkO1NFEh|ryP Mk[4V2FPT0WU
DOHH-2 NIi2R|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfITWM2OD1{LkSyNlc6KM7:TR?= NXX2b|RKW0GQR1XS
ES4 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\MSWlEPTB;Mj60N|E2PSEQvF2= MkDRV2FPT0WU
SW780 NFHyemJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTJwNUC4PFMh|ryP NH\CXYRUSU6JRWK=
VA-ES-BJ MlPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHiOZVsUUN3ME2yMlU1OTFizszN MnzOV2FPT0WU
RPMI-8866 NIr0OFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYftR4J2UUN3ME2yMlU3OjF2IN88US=> NGfJN5hUSU6JRWK=
ML-2 MlHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HuS2lEPTB;Mj61OlU4PiEQvF2= NFzpV3hUSU6JRWK=
MSTO-211H NESxRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTJwNUe0OVEh|ryP MkGyV2FPT0WU
JVM-3 MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjKbHZ5UUN3ME2yMlU6OzJ2IN88US=> MXzTRW5ITVJ?
A3-KAW M3r5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTJwNkG4NVgh|ryP MWfTRW5ITVJ?
DK-MG Mmm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJwNkK0O|Eh|ryP Mm\4V2FPT0WU
LNCaP-Clone-FGC MkT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmSwTWM2OD1{Lk[0N|E5KM7:TR?= M3vt[nNCVkeHUh?=
HT-144 NWjJZo9JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fDdmlEPTB;Mj62OFU4PyEQvF2= NEi2OFZUSU6JRWK=
NB69 NV3pfHRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\0fodKSzVyPUKuOlU{OzRizszN MmDvV2FPT0WU
A172 M3zYdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPXZ3RKSzVyPUKuOlc2QDhizszN MY\TRW5ITVJ?
RS4-11 M{\GO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULZepA{UUN3ME2yMlczPDB5IN88US=> MXzTRW5ITVJ?
DU-4475 M2WyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXTbGJJUUN3ME2yMlc6PTB{IN88US=> NWmwR3lwW0GQR1XS
SJSA-1 M17ldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrlTWM2OD1{LkiyOVU3KM7:TR?= MWTTRW5ITVJ?
BV-173 MlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXwV|FRUUN3ME2yMlg1PDN7IN88US=> MlrTV2FPT0WU
U-2-OS M2ezO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTJwOUGwO{DPxE1? NYHscJQ4W0GQR1XS
CHP-134 NYLLeFBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LsfmlEPTB;Mj65N|g5OiEQvF2= MnvNV2FPT0WU
D-502MG NIPiXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPCc5psUUN3ME2yMlk4OTV2IN88US=> NIPyR|VUSU6JRWK=
KS-1 Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFraOIVKSzVyPUOuNFE3OjNizszN MkH1V2FPT0WU
A204 NFXjSlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYToRldRUUN3ME2zMlA2PTh6IN88US=> NF7EVGtUSU6JRWK=
KGN NWWyPG9wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTNwMEi0PVYh|ryP M3fEcXNCVkeHUh?=
NCI-H292 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\OUHMyUUN3ME2zMlEzODJ6IN88US=> Mn3xV2FPT0WU
CAKI-1 MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojzTWM2OD1|LkGyOlk1KM7:TR?= NE\I[4hUSU6JRWK=
C2BBe1 MnHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3rUFlKSzVyPUOuNVcxOjZizszN Mn7tV2FPT0WU
NB10 NEXRemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTNwMkC5OlYh|ryP NXX3b5UxW0GQR1XS
MHH-NB-11 M1v0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2G2fWlEPTB;Mz6yOlgzPyEQvF2= M{TtbnNCVkeHUh?=
NCI-SNU-1 M13kfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PYcmlEPTB;Mz6yO|g1OyEQvF2= MV\TRW5ITVJ?
HCT-116 MkXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLHSmZKSzVyPUOuN|A{OzVizszN MkPSV2FPT0WU
G-401 NWPTbWU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjDU5VmUUN3ME2zMlM3OzJ{IN88US=> NHi2TGVUSU6JRWK=
MN-60 NWPPcHVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWj4eYRCUUN3ME2zMlQ1ODl{IN88US=> NUTxSYJMW0GQR1XS
SW982 NEfkW|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;HTWM2OD1|LkWwPFQ5KM7:TR?= NHfIc4ZUSU6JRWK=
RKO NIPqTZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXDUlNDUUN3ME2zMlU{QTN4IN88US=> NXT5Z2F7W0GQR1XS
D-283MED M2\TSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvYTWM2OD1|LkW3PVg3KM7:TR?= MV;TRW5ITVJ?
LB996-RCC Ml3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXXOlY{UUN3ME2zMlYzPTV6IN88US=> MVnTRW5ITVJ?
A549 NWTiW|RJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnTdlM1UUN3ME2zMlY{PTV{IN88US=> NH;wRnhUSU6JRWK=
LB2241-RCC MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rqPGlEPTB;Mz62OVcxQCEQvF2= NWTSbIdDW0GQR1XS
SK-HEP-1 NEXEVIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkG3TWM2OD1|Lke0Nlk4KM7:TR?= MlK1V2FPT0WU
G-402 NVXLVYozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPLTWM2OD1|LkiwPFMzKM7:TR?= MkPnV2FPT0WU
GOTO NVf2SVhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTNwOESzN|Mh|ryP NFzOZplUSU6JRWK=
LOXIMVI MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHaTWM2OD1|Lki1Olc2KM7:TR?= NFX6eJlUSU6JRWK=
NH-12 M17IUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTRwMEG5OVkh|ryP M1rXPHNCVkeHUh?=
CTV-1 NFzLcGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nW[2lEPTB;ND6wO|k4OyEQvF2= M3Wyd3NCVkeHUh?=
CP50-MEL-B M2L5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTpTWM2OD12LkK0N|kzKM7:TR?= MmPmV2FPT0WU
RH-18 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUL5NoRTUUN3ME20MlI4PzB4IN88US=> MV7TRW5ITVJ?
NB17 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2OwbWlEPTB;ND6zNVc3QCEQvF2= MYDTRW5ITVJ?
A375 NECyZ|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nuVWlEPTB;ND6zN|UzPCEQvF2= NV;jW2FjW0GQR1XS
IST-MES1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTRwNEG0NVEh|ryP M37iO3NCVkeHUh?=
MZ2-MEL MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHLVXZKSzVyPUSuOVAyPTVizszN NEXUZplUSU6JRWK=
CAL-54 NVvxTYp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvzPZpKSzVyPUSuOVMxOTlizszN NFHOb3dUSU6JRWK=
NCI-H28 M3zZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTCTlRUUUN3ME20MlYzPzF5IN88US=> M{XqcnNCVkeHUh?=
D-247MG NF:5XWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TsPGlEPTB;ND63OVA4OiEQvF2= NWm4Z45JW0GQR1XS
NCI-H460 M2W0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;3TWM2OD12LkmxNVI4KM7:TR?= M3npWXNCVkeHUh?=
MCF7 MnfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTVwNESyOFQh|ryP NFv2co5USU6JRWK=
697 NIK2bWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWH3fI5lUUN3ME21MlQ1PTVizszN MYDTRW5ITVJ?
ONS-76 MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DSW2lEPTB;NT61O|AxQSEQvF2= M{TUc3NCVkeHUh?=
C32 M3TyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTVwNkCwNlkh|ryP MXvTRW5ITVJ?
OS-RC-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH[0NG9KSzVyPUWuO|M5QDdizszN NH:1d4NUSU6JRWK=
MEL-HO MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTVwOEW2Olch|ryP M2PG[nNCVkeHUh?=
LoVo M4HmSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfWTWM2OD14LkCxOlI1KM7:TR?= MlPMV2FPT0WU
AGS M4fVUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTZwMUS4Nlgh|ryP NHvRdFlUSU6JRWK=
GI-ME-N MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTZwMkK0NlEh|ryP NFnmSVJUSU6JRWK=
H-EMC-SS NHPRbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\XNGFxUUN3ME22MlM5PiEQvF2= MnjKV2FPT0WU
RVH-421 NGDPcnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTMU3ZXUUN3ME22MlQzPDJ6IN88US=> M1zsbHNCVkeHUh?=
SW954 NXjqeY9pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;nSFFKSzVyPU[uOVU2PzJizszN MkXYV2FPT0WU
NB5 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\tTWM2OD14LkW2NVg{KM7:TR?= MVfTRW5ITVJ?
NCI-H2122 NFi4PGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\yTWM2OD14LkW4O|k{KM7:TR?= MYjTRW5ITVJ?
AM-38 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[2VGdKSzVyPU[uO|U3OzlizszN NVK3dlR7W0GQR1XS
KNS-81-FD M4GxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUX6c2U4UUN3ME22Mlc3PDl2IN88US=> MUHTRW5ITVJ?
LS-513 MnPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDOVnJFUUN3ME22Mlc6ODJ4IN88US=> NIrPZlJUSU6JRWK=
A427 M4LZb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPr[JNKSzVyPU[uPFc5OjlizszN NGD3cnNUSU6JRWK=
WM-115 NGm0PYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHX5XFBKSzVyPU[uPVMzOyEQvF2= NYfHVFgzW0GQR1XS
COLO-829 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHj6SmRKSzVyPUeuNlQyQDhizszN MXHTRW5ITVJ?
NCI-H1650 NXLCWG9MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTdwM{myNlgh|ryP NHu2XY5USU6JRWK=
NCI-H358 NXnLb3ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTdwNES4O|kh|ryP NVLrTZNkW0GQR1XS
HT-1080 NInOWWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFf5SmFKSzVyPUeuOFgzPTRizszN MUfTRW5ITVJ?
HCC2218 NVzIV2FDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3oU4hGUUN3ME23MlYzQTdizszN NE\Ve4RUSU6JRWK=
NCI-H661 MkfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXFfHA5UUN3ME23Mlg4ODZ7IN88US=> M3H0dnNCVkeHUh?=
KM-H2 Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrIclJKSzVyPUeuPFg3QTRizszN NYLLWHloW0GQR1XS
RPMI-2650 NVzZTIxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPlTWM2OD15Lkm0OFE1KM7:TR?= MkPRV2FPT0WU
NCI-H226 M2nLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWezTlQ6UUN3ME24MlIyOTJ{IN88US=> NX\uepNsW0GQR1XS
MKN45 M4iyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDRe41KSzVyPUiuNlY3ODJizszN MnrQV2FPT0WU
D-392MG MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRThwNUK3NlIh|ryP NY\XXmM6W0GQR1XS
RCC10RGB NVPpO5NWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDVTWM2OD16Lki2Olk2KM7:TR?= NWfDe2d5W0GQR1XS
CAL-51 M1nPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTlwMUCyOVEh|ryP MmW4V2FPT0WU
COLO-678 NY\GXJBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTlwM{K4NVEh|ryP MmG1V2FPT0WU
SK-MEL-24 MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnw[GFrUUN3ME25MlU2QDV4IN88US=> MlvQV2FPT0WU
SK-MEL-30 NVG1WHM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDybphKSzVyPUmuPVQ1PzZizszN NEfMSJFUSU6JRWK=
MMAC-SF NHXVT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DwWGlEPTB;MUCuN|k3OSEQvF2= NI\YUHNUSU6JRWK=
NTERA-S-cl-D1 NGj3ZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTFyLk[1NFgh|ryP MUHTRW5ITVJ?
NB12 NF;IcJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnWPI5KSzVyPUGxMlUxOyEQvF2= NXnrcWI{W0GQR1XS
UACC-257 NU\YXINvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17sd2lEPTB;MUGuPFY6PSEQvF2= NV7sVIpXW0GQR1XS
LAN-6 M3PJRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTFzLkm5Nlgh|ryP NV;yVGROW0GQR1XS
SW1573 MoT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4T3d2lEPTB;MUKuN|A5PiEQvF2= NInYS|BUSU6JRWK=
NMC-G1 NF7JcFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;qTWM2OD1zMj60NVc2KM7:TR?= Mn\SV2FPT0WU
SHP-77 M4GzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFy1UIJKSzVyPUGyMlU2PzRizszN MX;TRW5ITVJ?
IGROV-1 Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXxTWM2OD1zMj62OVc{KM7:TR?= MYLTRW5ITVJ?
22RV1 NUTFVYNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHFTWM2OD1zMj64NFU6KM7:TR?= Mmr6V2FPT0WU
SK-MEL-3 NX7lcZFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3aTWM2OD1zMz6zPVc{KM7:TR?= MUnTRW5ITVJ?
NCI-H1563 Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDkUpJKSzVyPUGzMlQzODJizszN NYXHdFRSW0GQR1XS
IGR-1 M1z6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TGOWlEPTB;MUSuNFM1PyEQvF2= MVXTRW5ITVJ?
EW-3 M4j5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPXTWM2OD1zND6xOlM6KM7:TR?= M3KwWXNCVkeHUh?=
JEG-3 MlfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILHNlhKSzVyPUG0MlQ6PTNizszN M{jGbXNCVkeHUh?=
ES3 NVzncJF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTF2Lk[1OlIh|ryP NE\scHZUSU6JRWK=
MDA-MB-175-VII NYHQSnd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTCZWlKSzVyPUG0MlcyOTFizszN NWnrdVdLW0GQR1XS
P30-OHK MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1q4NmlEPTB;MUWuNFQ6PiEQvF2= M2\B[HNCVkeHUh?=
GP5d M2jFN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTF3LkG0OlYh|ryP MorIV2FPT0WU
HMV-II MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPSdYZKSzVyPUG1MlM{OzNizszN NHzRb|NUSU6JRWK=
COLO-679 M3zrNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUm1TGhjUUN3ME2xOU42ODFizszN M1PlfHNCVkeHUh?=
JAR M2DwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rFVGlEPTB;MUWuO|IxPSEQvF2= MUPTRW5ITVJ?
NCI-H1666 NW\KXWxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIizSYJKSzVyPUG1Mlk{QTlizszN MlPJV2FPT0WU
SW48 NXzTNVR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzscZVKSzVyPUG1Mlk2OTZizszN Moi0V2FPT0WU
NCI-H720 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfBTWM2OD1zNT65PVg6KM7:TR?= MWfTRW5ITVJ?
HT-1197 NGLDO5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXyTWM2OD1zNj6wN|UzKM7:TR?= MWHTRW5ITVJ?
HL-60 NIG0cVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XINGlEPTB;MU[uNFM5PCEQvF2= MmPTV2FPT0WU
BEN Mn\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X6cWlEPTB;MU[uOVY{QCEQvF2= NFT5Z2NUSU6JRWK=
HAL-01 NF\6V|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTF4Lki5NFkh|ryP NXfpboRZW0GQR1XS
SW900 M4r0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TWUWlEPTB;MU[uPVE{OiEQvF2= M33J[HNCVkeHUh?=
SBC-1 NFn4R2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTF5LkW0Nlkh|ryP M2PyTHNCVkeHUh?=
SH-4 MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\Md4xnUUN3ME2xO{42QDRzIN88US=> M{TYWHNCVkeHUh?=
UACC-62 NV7NVZp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjUUmVpUUN3ME2xO{44PjN5IN88US=> Ml;hV2FPT0WU
BHT-101 NF70fHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjPXmNKSzVyPUG5Mlg4ODVizszN NVzWTJMyW0GQR1XS
DB M4TDfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWG2eZl{UUN3ME2yNU42PjR7IN88US=> NHrCdmtUSU6JRWK=
SK-MEL-1 NX:3OGtqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\LTWM2OD1{MT61PFczKM7:TR?= MlXOV2FPT0WU
NCI-H747 NYr2dpg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHVTWM2OD1{Mj63N|c6KM7:TR?= NVLKe49xW0GQR1XS
SK-LU-1 Mlq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTJ|LkO1NlQh|ryP Mn;pV2FPT0WU
KG-1 NX3QR|N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWC3[Xc4UUN3ME2yN{41QTR4IN88US=> M3TscHNCVkeHUh?=
LXF-289 MkDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrqTWM2OD1{Mz63NVQh|ryP NEXrb5BUSU6JRWK=
HCC1954 M2jOZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkX5TWM2OD1{ND64PFQ1KM7:TR?= NEHKXZNUSU6JRWK=
Ramos-2G6-4C10 M4q2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDzZYdKSzVyPUK2MlQ6QDFizszN M4\PdHNCVkeHUh?=
DBTRG-05MG MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTJ4Lk[0PFgh|ryP M13pPXNCVkeHUh?=
NCI-H2052 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnpXYdKSzVyPUK3MlU3QDRizszN Mn3VV2FPT0WU
RMG-I MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTNTWM2OD1{OT60NVM6KM7:TR?= NWPzZWdLW0GQR1XS
H9 M2q4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTNzLkOwNFgh|ryP M1KxPHNCVkeHUh?=
GR-ST NFO1O2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTN{LkS0OVMh|ryP M{PIOXNCVkeHUh?=
Mo-T MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jtTWlEPTB;M{KuOVA1PiEQvF2= MUnTRW5ITVJ?
SW1088 Mnz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1WxemlEPTB;M{KuPVgxOSEQvF2= NI[xNYpUSU6JRWK=
LB2518-MEL Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfhTWM2OD1|Mz6wO|k4KM7:TR?= NHPYUJRUSU6JRWK=
NCI-H82 NHrybXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjRfIRsUUN3ME2zN{4yPjZzIN88US=> NEXTTpdUSU6JRWK=
LAMA-84 Mn\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PEWmlEPTB;M{SuOlA4OyEQvF2= MWfTRW5ITVJ?
KYSE-450 MkHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPZTWM2OD1|ND62O|c3KM7:TR?= MV7TRW5ITVJ?
LU-99A NGHWc3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\4OWlEPTB;M{WuNFAxPyEQvF2= MXrTRW5ITVJ?
BE-13 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfBZXJ3UUN3ME2zOU43PTR3IN88US=> NEG4eHlUSU6JRWK=
GAK NYnyTIU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LkZ2lEPTB;M{WuOlk2KM7:TR?= MV;TRW5ITVJ?
NCI-H1573 NFz6clVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvhUGFKSzVyPUO1Mlg5OThizszN MX7TRW5ITVJ?
AsPC-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofjTWM2OD1|Nj6xOVI4KM7:TR?= M3LwbXNCVkeHUh?=
HDLM-2 NX7UdYRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofFTWM2OD1|Nj6zNVYh|ryP MlrnV2FPT0WU
NCI-H441 M2nVT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGKxRndKSzVyPUO3MlA3QTFizszN MnrpV2FPT0WU
CAL-27 NEC0OY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfnUXQ1UUN3ME2zO{44OjNzIN88US=> M4XT[3NCVkeHUh?=
OVCAR-3 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXmTWM2OD1|OT6zNVgyKM7:TR?= NEfMVXdUSU6JRWK=
RPMI-8226 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1KxcmlEPTB;M{muOVk5KM7:TR?= MVrTRW5ITVJ?
EFO-21 M2HwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPtW2dZUUN3ME20NE42QDF2IN88US=> NYDFdJhoW0GQR1XS
SNU-C2B M1u2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLzWZNNUUN3ME20NU42ODh2IN88US=> NFPNWGRUSU6JRWK=
VM-CUB-1 NGHwUJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3ZTWM2OD12Mz64NFM4KM7:TR?= M3zBXXNCVkeHUh?=
NCI-H2087 NHjr[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTufIZZUUN3ME20OU4xOjN|IN88US=> NFzUXXJUSU6JRWK=
EW-16 NEPDZ5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fXXWlEPTB;NE[uN|E{PyEQvF2= MYfTRW5ITVJ?
SK-N-AS MnvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTR4LkexOlch|ryP MWXTRW5ITVJ?
COR-L105 NUf6cYlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTR4Lki4OVch|ryP NH6zTHlUSU6JRWK=
DEL NEfReWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfJR|lXUUN3ME20PE4xPDJ7IN88US=> NIfndoZUSU6JRWK=
JVM-2 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3GyT2lEPTB;NEiuNFU2QCEQvF2= MkmwV2FPT0WU
KARPAS-45 NGqyZmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2m1NmlEPTB;NEmuOFU{QCEQvF2= NVz6dJRVW0GQR1XS

... Click to View More Cell Line Experimental Data

体内研究 Nutlin-3α以剂量依赖性方式抑制异种移植物生长,在最高剂量(200毫克/千克)时表现大量的肿瘤收缩。Nutlin-3是p53途径在体内的选择性活化剂,并高度有效地抗SJSA-1骨肉瘤。有野生型p53和MDM2基因扩增的肿瘤对Nutlin-3α治疗应答最好。 [1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[3]
+ 展开

Biacore研究:

竞争分析是在Biacore S51进行。甲系列S传感器芯片CM5衍生化用于固定一个PentaHis抗体来捕获His-标记的p53。捕获的水平是〜200响应单位(1单位响应对应于每毫米21 pg的蛋白质)。 MDM2蛋白的浓度被保持恒定在300 nM。将试验化合物溶解于10 mM DMSO中,并进一步稀释使每个MDM2测试样品中的浓度系列抑制剂。该试验是在25¡交流的电泳缓冲液(10 mM HEPES,0.15M的NaCl,2%DMSO)中运行。 MDM2-p53在抑制剂存在下的结合的计算方法是在没有抑制剂的结合的百分比,IC 50是使用微软EXCE计算。
细胞实验:[2]
+ 展开
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120小时
  • Method: SRB
    (Only for Reference)
动物实验:[1]
+ 展开
  • Animal Models: SJSA-1移植体
  • Formulation: 1% Klucel, 0.1% Tween 80
  • Dosages: 50, 100, 200 毫克/千克 每天两次
  • Administration: 口服
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+55% PEG 300+ddH2O
8mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 581.49
化学式

C30H30Cl2N4O4

CAS号 675576-98-4
稳定性 powder
in solvent
别名 (-)-Nutlin-3

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    What is the difference between S1061 (Nutlin-3) and S8059 (Nutlin-3a)?

  • 回答:

    S1061 is a racemic mixture of Nutlin3a and Nutlin3b. s8059 is the active enantiomer of Nutlin3.

Mdm2 Signaling Pathway Map

相关Mdm2产品

Tags: 购买Nutlin-3a | Nutlin-3a供应商 | 采购Nutlin-3a | Nutlin-3a价格 | Nutlin-3a生产 | 订购Nutlin-3a | Nutlin-3a代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID